BioPharma Credit PLC (FRA:B3P)
Germany
· Delayed Price · Currency is EUR 0.7800
0.00 (0.00%)
At close: Dec 4, 2025
BioPharma Credit Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Cash & Equivalents | 4.31 | 5.62 | 135.05 | 120.53 | 94.71 | 193.27 | Upgrade
|
| Cash & Short-Term Investments | 4.31 | 5.62 | 135.05 | 120.53 | 94.71 | 193.27 | Upgrade
|
| Cash Growth | -88.41% | -95.84% | 12.05% | 27.26% | -51.00% | -34.85% | Upgrade
|
| Accounts Receivable | 54.21 | 31.71 | 20.23 | 19.73 | 9.59 | 0 | Upgrade
|
| Other Receivables | 0.46 | 0.08 | 0.09 | 0.11 | 0.42 | 0.21 | Upgrade
|
| Receivables | 54.67 | 31.8 | 20.32 | 19.84 | 10.01 | 0.21 | Upgrade
|
| Total Current Assets | 58.98 | 37.42 | 155.37 | 140.37 | 104.72 | 193.48 | Upgrade
|
| Long-Term Investments | 1,099 | 1,162 | 1,201 | 1,224 | 1,266 | 1,195 | Upgrade
|
| Total Assets | 1,158 | 1,200 | 1,357 | 1,364 | 1,371 | 1,388 | Upgrade
|
| Accrued Expenses | 7.49 | 16.94 | 15.87 | 24.35 | 6.34 | 9.39 | Upgrade
|
| Other Current Liabilities | - | 0.95 | - | 1.95 | - | - | Upgrade
|
| Total Current Liabilities | 7.49 | 17.88 | 15.87 | 26.3 | 6.34 | 9.39 | Upgrade
|
| Long-Term Unearned Revenue | - | 0.06 | - | 0.26 | 0.56 | - | Upgrade
|
| Total Liabilities | 7.49 | 17.94 | 15.87 | 26.56 | 6.9 | 9.39 | Upgrade
|
| Common Stock | 13.74 | 13.74 | 13.74 | 13.74 | 13.74 | 13.74 | Upgrade
|
| Additional Paid-In Capital | 607.13 | 607.13 | 607.13 | 607.13 | 607.13 | 607.13 | Upgrade
|
| Retained Earnings | 529.45 | 560.81 | 720 | 716.59 | 742.85 | 758.05 | Upgrade
|
| Shareholders' Equity | 1,150 | 1,182 | 1,341 | 1,337 | 1,364 | 1,379 | Upgrade
|
| Total Liabilities & Equity | 1,158 | 1,200 | 1,357 | 1,364 | 1,371 | 1,388 | Upgrade
|
| Net Cash (Debt) | 4.31 | 5.62 | 135.05 | 120.53 | 94.71 | 193.27 | Upgrade
|
| Net Cash Growth | -88.41% | -95.84% | 12.05% | 27.26% | -51.00% | -34.85% | Upgrade
|
| Net Cash Per Share | 0.00 | 0.00 | 0.10 | 0.09 | 0.07 | 0.14 | Upgrade
|
| Filing Date Shares Outstanding | 1,129 | 1,140 | 1,254 | 1,319 | 1,374 | 1,374 | Upgrade
|
| Total Common Shares Outstanding | 1,129 | 1,186 | 1,303 | 1,319 | 1,374 | 1,374 | Upgrade
|
| Working Capital | 51.48 | 19.53 | 139.5 | 114.06 | 98.38 | 184.08 | Upgrade
|
| Book Value Per Share | 1.02 | 1.00 | 1.03 | 1.01 | 0.99 | 1.00 | Upgrade
|
| Tangible Book Value | 1,150 | 1,182 | 1,341 | 1,337 | 1,364 | 1,379 | Upgrade
|
| Tangible Book Value Per Share | 1.02 | 1.00 | 1.03 | 1.01 | 0.99 | 1.00 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.